Small molecules for perturbing iron homeostasis in bacterial biofilms

扰乱细菌生物膜中铁稳态的小分子

基本信息

批准号：
10573309
负责人：
Mario Rivera
金额：
$ 72.86万
依托单位：
LOUISIANA STATE UNIV A&M COL BATON ROUGE
依托单位国家：
美国
项目类别：
财政年份：
2022
资助国家：
美国
起止时间：
2022-02-15 至 2027-01-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10573309
关键词：
Acinetobacter baumannii Address Affect Affinity Animal Model Anti-Bacterial Agents Anti-Infective Agents Antibiotic Resistance Antibiotic Therapy Antibiotic susceptibility Antibiotics Bacteria Binding Binding Sites Biology Cell Death Cell Survival Cells Chemicals Chronic Clinical Complex Cytosol Drug Industry Effectiveness Elderly Electron Transport Environment Escherichia Generations Genes Gram-Negative Bacteria Health care facility Healthcare Homeostasis Immune response Impairment Infection Invaded Ions Iron Laser Scanning Confocal Microscopy Lead Long-Term Care Maintenance Mammalian Cell Metabolism Microbial Biofilms Microbial Genetics Modification Multi-Drug Resistance Mus Mutation Organic Synthesis Patient Admission Pharmaceutical Chemistry Pharmaceutical Preparations Phenotype Physiological Predisposition Proteins Pseudomonas aeruginosa Reaction Resistance Resistance development Staphylococcus aureus Structure Synthesis Chemistry Testing Theft Work Wound Infection Wound models X-Ray Crystallography analog antibiotic tolerance antimicrobial bactericide chronic wound combat cytotoxicity deprivation design diabetic patient drug development drug discovery experience improved in vivo in vivo Model inhibitor insight iron metabolism medical schools next generation novel pathogen protein complex protein protein interaction rational design research and development resistant strain small molecule small molecule inhibitor structural biology synergism tool tool development wound care

项目摘要

ABSTRACT Chronic wound care is especially complicated by the formation of bacterial biofilms, commonly by Pseudomonas aeruginosa, Acinetobacter baumannii and Staphylococcus aureus. Biofilms are recalcitrant to antibiotic therapy, which is an important reason why chronic wound infections are so difficult to eradicate. There is a significant need to discover new strategies to combat biofilms. Bacterial iron homeostasis is a suitable novel target for developing anti-infectives because the host makes essential iron scarce to invading pathogens. Bacteria have evolved mechanisms to “steal” iron from their host, but these depend on well-regulated iron homeostasis. To disrupt bacterial iron homeostasis, we are targeting the iron storage protein BfrB and its physiological partner protein, Bfd, which are unique to bacteria. Our work has shown that BfrB regulates cytosolic iron concentrations by (a) oxidizing Fe2+ and storing up to ~3,000 Fe3+ ions in its internal cavity, and (b) forming a complex with Bfd to reduce Fe3+ in the internal cavity of BfrB and release Fe2+ to the cytosol for its incorporation in metabolism. Blocking the BfrB-Bfd complex in P. aeruginosa cells by deletion of the bfd gene perturbs iron homeostasis by triggering an irreversible accumulation of Fe3+ in BfrB and simultaneous cytosolic iron depletion, which leads to impaired biofilm maintenance and biofilm cell death. Our work also led to the discovery of proof-of-concept inhibitors of the BfrB-Bfd complex, which bind BfrB at the Bfd binding site, inhibit iron mobilization, and elicit biofilm cell death. The objectives of this application are to improve the proof-of-concept molecules into lead molecules, evaluate their antibacterial and antibiofilm effectiveness, and evaluate their potential drug suitability. Our interdisciplinary team includes expertise in chemical and structural biology of bacterial iron homeostasis (Rivera), organic synthesis and reaction mechanisms (Bunce), pharmaceutical industry research and development of anti-infectives (Reitz), X-ray crystallography in drug discovery (Lovell), microbial genetics (Chandler), and animal model of infection (Morici). The specific aims are: 1) Evolve proof-of-concept analogs into potent inhibitors of the BfrB-Bfd complex. This work will follow a systematic, iterative strategy of medicinal chemistry synthesis optimization that relies on crystal structures of inhibitor bound BfrB to design each new generation of inhibitors. 2) Asses the antibacterial effectiveness of inhibitors of the BfrB-Bfd complex and evaluate their potential drug suitability.

抽象的细菌生物膜（通常是假单胞菌）的形成使慢性伤口护理变得尤其复杂铜绿假单胞菌、鲍曼不动杆菌和金黄色葡萄球菌生物膜对抗生素治疗有抵抗力，这是慢性伤口感染难以根除的重要原因。需要发现对抗生物膜的新策略，细菌铁稳态是一个合适的新目标。开发抗感染药物是因为宿主使入侵的细菌缺乏必需的铁。进化出从宿主“窃取”铁的机制，但这些机制依赖于良好调节的铁稳态。破坏细菌铁稳态，我们的目标是铁储存蛋白 BfrB 及其生理伙伴蛋白质，Bfd，是细菌特有的，我们的工作表明 BfrB 调节细胞质铁浓度。通过 (a) 氧化 Fe2+ 并在其内腔中储存多达约 3,000 个 Fe3+ 离子，以及 (b) 与 Bfd 形成复合物还原 BfrB 内腔中的 Fe3+ 并将 Fe2+ 释放到细胞质中以参与代谢。通过删除 bfd 基因来阻断铜绿假单胞菌细胞中的 BfrB-Bfd 复合物，从而扰乱铁稳态触发 BfrB 中 Fe3+ 不可逆积累，同时胞质铁耗尽，从而导致我们的工作还导致了概念验证的发现。 BfrB-Bfd 复合物的抑制剂，在 Bfd 结合位点结合 BfrB，抑制铁动员，并引发该应用的目的是将概念验证分子改进为铅。分子，评估其抗菌和抗生物膜有效性，并评估其潜在的药物适用性。我们的跨学科团队包括细菌铁稳态的化学和结构生物学方面的专业知识（Rivera）、有机合成与反应机理（Bunce）、制药工业研究与抗感染药物的开发 (Reitz)、药物发现中的 X 射线晶体学 (Lovell)、微生物遗传学 (Chandler) 和感染动物模型 (Morici) 具体目标是：1) 发展概念验证类似物。转化为 BfrB-Bfd 复合物的有效抑制剂这项工作将遵循系统的、迭代的药物策略。化学合成优化依赖于抑制剂结合 BfrB 的晶体结构来设计每个新的 2) 评估 BfrB-Bfd 复合物抑制剂的抗菌效果评估其潜在的药物适用性。